HIVNCT04108078
Promoting Reductions in Intersectional StigMa (PRISM) - GHANA
A study testing Health Policy Plus (HP+), Many Men Many Voices (3MV) and HIV Education, Empathy and Empowerment (HIVE3) in people with HIV and Stigma, run by Yale University at 1 site in Ghana.
Trial summary
HIV prevalence among men with have sex with men (MSM) in Ghana is at least eight times higher than that of the general population (2%). MSM in Ghana face high levels of stigma due to HIV status (actual or perceived), same-sex behavior, and gender non-conformity. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- What is being tested?
- Health Policy Plus (HP+), Many Men Many Voices (3MV) and HIV Education, Empathy and Empowerment (HIVE3)
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 549 participants
- Where
- 1 siteGhana
- Study dates
- 1 Oct 2020to 31 Dec 2022
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- For the RCT, HCF staff are eligible to participate in the study if they are:
- Employed at one of the eight facilities identified for this study and identified with a potential to encounter MSM clients.
- For the RCT, MSM are eligible to participate in the study if they are:
- Biologically male at birth
- Currently self-identify as cisgender man
- Report sexual activity with another man at least once within the previous six months and report that they are HIV-negative or status unknown.
Show all 23Show fewer
- HCF staff are eligible to participate in the FGDs if they are:
- Employed at a study participating facility.
- MSM are eligible to participate in FGDs if they are:
- 18 years or older
- Biologically male at birth
- Currently self-identified as cisgender man
- Reported sex with another man at least once within the previous six months. Note: HIV status is not an inclusion criterion for MSM FGD participation.
- In-Depth Interviews (IDI)
- HCF staff are eligible to participate if they are:
- Trained in Health Policy Plus (HP+)
- Have previously delivered HP+ in a Ghanaian HCF
- MSM are eligible to participate if:
- 18 years or older
- Biologically male at birth
- Currently self-identified as cisgender man
- Reported sex with another man at least once within the previous six months
- Self-reported that they are living with HIV
Who cannot join
- HCF staff will be excluded if they anticipate leaving work at the HCF during the study period or have previously participated in HP.
- MSM will be excluded if they plan to move out of the area during the study period.
- Focus Group Discussions (FGDs)
- Those who do not meet the inclusion criteria listed above
Trial locations and contacts
1 site in 1 country.
Ghana1 site
University of Ghana School of Public Health
Accra, Greater Accra Region
About this study
Official title: Multi-Level Intervention Addressing Intersectional Stigma to Improve HIV Testing in MSM
HIV prevalence among men with have sex with men (MSM) in Ghana is at least eight times higher than that of the general population (2%). MSM in Ghana face high levels of stigma due to HIV status (actual or perceived), same-sex behavior, and gender non-conformity. These stigmas are documented barriers to HIV prevention and treatment. In our preliminary work in Ghana (N=137), one-third of MSM had never been tested for HIV. This study is a randomized controlled trial to evaluate the feasibility, acceptability and estimate effect size of a multi-component, multi-level (organizational, interpersonal, and intrapersonal-level) intersectional stigma-reduction intervention to increase HIV testing frequency among MSM in Ghana where HIV, same-sex behavior and gender non-conformity are highly stigmatized. To date, stigma-reduction interventions in Ghana have focused on uni-level targets (e.g., health care facilities (HCFs)) and addressed one type of stigma (e.g., HIV), without engaging the intersectional character of the multiple stigmas that MSM encounter.
Our specific aims are:
Read more
- to evaluate the feasibility and acceptability of a novel multi-component, multi-level intervention to address intersectional stigma.
- to estimate effect size of the intervention for scale up to a definitive efficacy trial.
Our primary endpoint are:
For MSM: HIV testing, intervention feasibility and acceptability For HCFs: intervention feasibility, acceptability and appropriateness
Our secondary endpoints are:
MSM: Intersectional stigma reduction HCF: Intersectional stigma reduction
This study will combine three theory-based interventions that were previously implemented separately in Ghana for reducing stigma at HCF-level, increasing HIV testing at the peer group-level, and increasing peer social support at the individual-level. Convergence Framework will be used for combining interventions. The ADAPT-ITT framework guides our approach to enhancing the interventions' content on intersectional stigma. To achieve these aims a systematic adaptation that will be used to refine the individually developed HCF, peer- and individual-level interventions to produce a comprehensive multi-level intersectional stigma reduction intervention.
Read the detailed description
STUDY DESCRIPTION OVERVIEW. Our goal in this study is to determine the feasibility, acceptability and preliminary estimate of effect size of a multi- level intersectional stigma-reduction intervention on HIV testing among MSM in Ghana. This study has two phases: a formative phase and a test phase. The eight-step ADAPT-ITT framework will guide our approach to enhancing the interventions' content to address intersectional stigma and combine the three separate interventions into one multi- level approach. Aim 1 will encompass steps 1-7, leading to the combined multi-level intervention adapted to deepen intersectional stigma content and step 8 in which the study team will conduct a waitlist-controlled RCT of the adapted intervention for feasibility and acceptability. In Aim 2, data generated in the RCT will be used to estimate the effect size of the multi-level intervention on HIV testing among MSM (primary outcome) and intersectional stigma reduction (secondary outcome) among the MSM and HCF staff. In deciding on the RCT with wait-list control was considered with other designs such as factorial designs and a classic RCT design with time and attention-matched controls. It was determined that the RCT with wait-list control was superior to the other designs because our study is premised on the need for combined interventions. Since it is not intended yet to seek to isolate which component of the intervention had the greatest effect on our outcomes, a factorial design was not scientifically justified for our proposed study. Additionally, ethical and budgetary considerations informed our decision to forgo using a structurally equivalent control in favor of a wait-list control for the intervention given the evidence of each interventions' efficacy for reducing stigma among HCF staff and improving HIV testing among MSM.
FORMATIVE PHASE STEP 1: ASSESS Focus group discussions (FGDs) and in-depth interviews (IDIs) will be conducted with MSM and HCF staff to inform the adaptation of the three existing interventions to deepen intersectional stigma content and their integration with each other to address intersectional stigma at multiple levels. FGDs were chosen because of their demonstrated suitability in studies of sexual health and to capitalize on the spontaneous conversational interaction that occurs in groups. This re-creation of the social dynamic with the HCF staff and MSM is critical to the understanding of intersectional stigma from the social organization of these two groups. There are also plans to conduct a limited set of individual interviews to examine more in-depth, topics that elicit intimate personal accounts that may not be suitable for sharing in groups. For example, MSM PLHIV are targeted for IDIs to gain insight into whether and how intersectional stigma experiences influenced their pre- diagnosis prevention behaviors, access to prevention services, timing of HIV testing and linkage to care post-diagnosis.
Qualitatively, the following will be investigated:
- the drivers and manifestations of HIV, same-sex and gender non-conforming stigmas (intersectional stigma) within HCFs and MSM peer groups
- how these intersecting stigmas undermine HIV testing
- perspectives on strategies for reducing intersectional stigma within HCFs and among MSM peer groups. This information will guide to what degree and how these stigmas are addressed within the intervention.
In each study city (Accra and Kumasi), 2-4 FGDs will take place in each with HCF staff and MSM, as well as IDIs with HP+ trainers from the pilot phase (n=10) and MSM with HIV (n=8). The purpose and expectations of involvement in the study will be explained to prospective participants.
STEP 2: DECIDE Guided by the formative research results, the team will meet to discuss what specific intervention activities should be modified to address intersectional stigma. An updated scoping review of research literature to identify innovative evidence-based options to enhance focus on intersecting stigmas, with special attention to technology and social media options. This will include a review of the current intervention activities and discussion of how they can be refined to address intersecting stigmas. In consultation with our civil society partners, the team will then incorporate these changes into the curriculum, identify gaps/errors in logic and make corrections in preparation to conduct a workshop of the intervention with key reference groups.
STEP 3: ADMINISTER After initial modifications, a facilitated simulation workshop of the intervention activities with a combined group of HP+ HCF staff (n=4) and client trainers (n=2) who delivered HP+ in other health facilities in Ghana and MSM (n=8) who received the original 3MV and HIVE3 interventions will take place. Then, the team will conduct a joint workshop session because it is consistent with the concept that the intervention must retain relevance to MSM at all points along the HIV testing pathway, including in the HCF and among their peer-groups. The next step will be produce a revised combined version of the original intervention manuals before the workshop and conduct a series of facilitated simulation exercises with role-play over a 4-day period. Participants will work through each of the intervention levels, focusing on the intersectional stigma content and reviewing our approach to linking the different levels and creating opportunities for safe contact between HCF staff and MSM.
STEP 4: PRODUCE Based on the feedback from the simulation workshop participants and our observations of their engagement with the activities, the study team will determine what content and approaches to incorporate into the adapted intervention manual and which content and processes to edit or forego. In our decision-making process, the study team will give priority consideration to maintaining components that have the highest consistency with scientific literature on intersectional stigma, local cultural relevance, and likelihood to be fun/enjoyable-key requisites for successful intervention uptake.
STEP 5: TOPIC The study team will engage topic experts to review the adapted manual and provide feedback on its congruence with the original intervention and local sociocultural relevance. A copy of the adapted, combined multi-level intervention manual will be provided to the principal investigators of the original separate level interventions. Ghanaian MSM who lead PORSH and YAHR (our two civil-society organization partners that work with Ghanaian MSM) will give feedback that is key to the local cultural relevance and intervention implementation.
STEP 6: INTEGRATE In this step, feedback provided by the topic experts will be taken and summarized in a report that will be distributed to the entire investigative team, including our key local partners. The feedback will be discussed to develop follow-up clarifying questions to the topic experts, as necessary, before making final revisions to the multi-level intervention manual.
STEP 7: TRAIN The study team will also produce a training manual to standardize training and permit future replication of the intervention in other settings. This will provide comprehensive training to study staff whose roles are dedicated to delivering the intervention. In addition, the development of multi-faceted training will take place to facilitate comprehension and retention of training concepts, using strategies that Drs. Nyblade and Nelson has successfully deployed in other HIV prevention research projects. This will include conducting a joint (including teams from both cities) rehearsal of the protocol prior to implementation in the RCT with HCF staff and MSM who are not part of the trial.
RANDOMIZATION PROCEDURES Matched pairing of study facilities: the study will assign four HCFs in each study city to intervention and control groups by matching the size of HCF facility staff censure. In every city, the plan is to first stratify four clinics into a pair of two larger clinics and a pair of two smaller clinics, and then randomly assign one larger and one smaller clinic to either arm. HCFs will be assigned using a randomization sequence created in SAS 9.4 with a 1:1 allocation using random block sizes of four by an independent research assistant. A separate research assistant will open the sealed envelopes to identify group assignment immediately after completion of baseline data collection.
Random assignment of MSM participants. Consented/eligible MSM will be randomized in a 1:1 ratio to intervention versus control arm. A block-randomization approach using a random numbers generator to assign participants to the study arms will be employed, which ensures that the number of participants assigned to the intervention arm in each of the two study cities (or blocks) is approximately equal to the control arm.
- Being tested
- Health Policy Plus (HP+), Many Men Many Voices (3MV), HIV Education, Empathy and Empowerment (HIVE3)
- Keywords
- HIV, Stigma, Intersectional Stigma, Men who have sex with men
- Medical subject headings
- Social Stigma, Homosexuality
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Health Policy Plus (HP+)Behavioural
HP+ is a stigma-reduction intervention that is designed to reduce stigmatizing attitudes and beliefs among all workers (clinical and non- clinical) in a healthcare facility.
Many Men Many Voices (3MV)Behavioural
3MV is a group-level HIV prevention intervention designed specifically for use with Black men who have sex with men (MSM). It is a 7- session intervention that is facilitated by trained peers. The intervention has previously been adapted and used with MSM in Ghana.
HIV Education, Empathy and Empowerment (HIVE3)Behavioural
The HIVE3 is a telephone-based peer support intervention. It utilizes trained peers, who are also MSM, to provide emotional, informational and affirming support via text message or phone. The intervention was developed specifically for use with MSM in Ghana and demonstrated acceptability and feasibility in a preliminary study in Ghana.
| Study group | Role | What they receive |
|---|---|---|
| Intervention | Experimental | This arm consists of 1) MSM who receive the intervention (not wait listed) and healthcare facility staff who work at health facilities that have been chosen for the intervention. Receives: Behavioral: Health Policy Plus (HP+); Behavioral: Many Men Many Voices (3MV); Behavioral: HIV Education, Empathy and Empowerment (HIVE3) |
| Wait listed | No intervention | Participants in this arm (MSM and staff at health facilities that were wait listed) will complete assessments, but will receive the intervention after the experimental arm of the study. |
What is being measured
The primary outcome is the main question the study is designed to answer.
HIV testing frequency (for MSM)
The intervention will be assessed in the number of completed HIV tests at 3 months compared to baseline. We will combine non-duplicative numbers of self-report and clinic-verified HIV tests (verification is only if an MSM had an HIV test performed at one of the healthcare facilities participating in the multi-level intervention) we are only measuring this outcome with MSM.
Measured: Change from baseline at 3 months post- intervention
HIV testing frequency (for MSM)
The intervention will be assessed in the number of completed HIV tests at 6 months compared to baseline. We will combine non-duplicative numbers of self-report and clinic-verified HIV tests (verification is only if an MSM had an HIV test performed at one of the healthcare facilities participating in the multi-level intervention) we are only measuring this outcome with MSM.
Measured: Change from baseline at 6 months post- intervention
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Sep 2019
- Study start1 Oct 2020
- Primary completion31 Dec 2022
- Study completion31 Dec 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for HIVStudies of the same condition, open and under way.
- More trials run by Yale UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Sequential
- Masking
- None (open label)
- Enrolment
- 549 participants (actual)
Sponsor and investigators
- Lead sponsor
- Yale University
- Sponsor type
- University, hospital or other
- Collaborators
- National Institute of Nursing Research (NINR)
- Responsible party
- Sponsor
- Investigators
- LaRon E. Nelson, PhD, Principal investigator, Yale School of Nursing
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04108078
- Sponsor's protocol ID
- 2000025917
- Other IDs
- 1R01NR019009-01
- Status last verified
- Mar 2023
- First submitted
- 9 Aug 2019
- Last updated
- 6 Mar 2023
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Nelson LE, Nyblade L, Torpey K, Logie CH, Qian HZ, Manu A, Gyamerah E, Boakye F, Appiah P, Turner D, Stockton M, Abubakari GM, Vlahov D. Multi-level intersectional stigma reduction intervention to increase HIV testing among men who have sex with men in Ghana: Protocol for a cluster randomized controlled trial. PLoS One. 2021 Nov 29;16(11):e0259324. doi: 10.1371/journal.pone.0259324. eCollection 2021.
PubMed 34843529
Study at a glance
From the registry record, last updated by the sponsor on 6 Mar 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Multi-Level Intervention Addressing Intersectional Stigma to Improve HIV Testing in MSM
- ClinicalTrials.gov ID
- NCT04108078
- Acronym / sponsor ID
- 2000025917
- Keywords
- HIV, Stigma, Intersectional Stigma, Men who have sex with men
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 549 participants (actual)
- Lead sponsor
- Yale UniversityUniversity, hospital or other
- Collaborators
- National Institute of Nursing Research (NINR)
- Study start
- 1 Oct 2020 (actual)
- Primary completion
- 31 Dec 2022 (actual)
- Study completion
- 31 Dec 2022 (actual)
- First posted
- 27 Sep 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
HIV prevalence among men with have sex with men (MSM) in Ghana is at least eight times higher than that of the general population (2%). MSM in Ghana face high levels of stigma due to HIV status (actual or perceived), same-sex behavior, and gender non-conformity. These stigmas are documented barriers to HIV prevention and treatment. In our preliminary work in Ghana (N=137), one-third of MSM had never been tested for HIV. This study is a randomized controlled trial to evaluate the feasibility, acceptability and estimate effect size of a multi-component, multi-level (organizational, interpersonal, and intrapersonal-level) intersectional stigma-reduction intervention to increase HIV testing frequency among MSM in Ghana where HIV, same-sex behavior and gender non-conformity are highly stigmatized. To date, stigma-reduction interventions in Ghana have focused on uni-level targets (e.g., health care facilities (HCFs)) and addressed one type of stigma (e.g., HIV), without engaging the intersectional character of the multiple stigmas that MSM encounter.
Our specific aims are:
- to evaluate the feasibility and acceptability of a novel multi-component, multi-level intervention to address intersectional stigma.
- to estimate effect size of the intervention for scale up to a definitive efficacy trial.
Our primary endpoint are:
For MSM: HIV testing, intervention feasibility and acceptability For HCFs: intervention feasibility, acceptability and appropriateness
Our secondary endpoints are:
MSM: Intersectional stigma reduction HCF: Intersectional stigma reduction
This study will combine three theory-based interventions that were previously implemented separately in Ghana for reducing stigma at HCF-level, increasing HIV testing at the peer group-level, and increasing peer social support at the individual-level. Convergence Framework will be used for combining interventions. The ADAPT-ITT framework guides our approach to enhancing the interventions' content on intersectional stigma. To achieve these aims a systematic adaptation that will be used to refine the individually developed HCF, peer- and individual-level interventions to produce a comprehensive multi-level intersectional stigma reduction intervention.
Detailed description
STUDY DESCRIPTION OVERVIEW. Our goal in this study is to determine the feasibility, acceptability and preliminary estimate of effect size of a multi- level intersectional stigma-reduction intervention on HIV testing among MSM in Ghana. This study has two phases: a formative phase and a test phase. The eight-step ADAPT-ITT framework will guide our approach to enhancing the interventions' content to address intersectional stigma and combine the three separate interventions into one multi- level approach. Aim 1 will encompass steps 1-7, leading to the combined multi-level intervention adapted to deepen intersectional stigma content and step 8 in which the study team will conduct a waitlist-controlled RCT of the adapted intervention for feasibility and acceptability. In Aim 2, data generated in the RCT will be used to estimate the effect size of the multi-level intervention on HIV testing among MSM (primary outcome) and intersectional stigma reduction (secondary outcome) among the MSM and HCF staff. In deciding on the RCT with wait-list control was considered with other designs such as factorial designs and a classic RCT design with time and attention-matched controls. It was determined that the RCT with wait-list control was superior to the other designs because our study is premised on the need for combined interventions. Since it is not intended yet to seek to isolate which component of the intervention had the greatest effect on our outcomes, a factorial design was not scientifically justified for our proposed study. Additionally, ethical and budgetary considerations informed our decision to forgo using a structurally equivalent control in favor of a wait-list control for the intervention given the evidence of each interventions' efficacy for reducing stigma among HCF staff and improving HIV testing among MSM.
FORMATIVE PHASE STEP 1: ASSESS Focus group discussions (FGDs) and in-depth interviews (IDIs) will be conducted with MSM and HCF staff to inform the adaptation of the three existing interventions to deepen intersectional stigma content and their integration with each other to address intersectional stigma at multiple levels. FGDs were chosen because of their demonstrated suitability in studies of sexual health and to capitalize on the spontaneous conversational interaction that occurs in groups. This re-creation of the social dynamic with the HCF staff and MSM is critical to the understanding of intersectional stigma from the social organization of these two groups. There are also plans to conduct a limited set of individual interviews to examine more in-depth, topics that elicit intimate personal accounts that may not be suitable for sharing in groups. For example, MSM PLHIV are targeted for IDIs to gain insight into whether and how intersectional stigma experiences influenced their pre- diagnosis prevention behaviors, access to prevention services, timing of HIV testing and linkage to care post-diagnosis.
Qualitatively, the following will be investigated:
- the drivers and manifestations of HIV, same-sex and gender non-conforming stigmas (intersectional stigma) within HCFs and MSM peer groups
- how these intersecting stigmas undermine HIV testing
- perspectives on strategies for reducing intersectional stigma within HCFs and among MSM peer groups. This information will guide to what degree and how these stigmas are addressed within the intervention.
In each study city (Accra and Kumasi), 2-4 FGDs will take place in each with HCF staff and MSM, as well as IDIs with HP+ trainers from the pilot phase (n=10) and MSM with HIV (n=8). The purpose and expectations of involvement in the study will be explained to prospective participants.
STEP 2: DECIDE Guided by the formative research results, the team will meet to discuss what specific intervention activities should be modified to address intersectional stigma. An updated scoping review of research literature to identify innovative evidence-based options to enhance focus on intersecting stigmas, with special attention to technology and social media options. This will include a review of the current intervention activities and discussion of how they can be refined to address intersecting stigmas. In consultation with our civil society partners, the team will then incorporate these changes into the curriculum, identify gaps/errors in logic and make corrections in preparation to conduct a workshop of the intervention with key reference groups.
STEP 3: ADMINISTER After initial modifications, a facilitated simulation workshop of the intervention activities with a combined group of HP+ HCF staff (n=4) and client trainers (n=2) who delivered HP+ in other health facilities in Ghana and MSM (n=8) who received the original 3MV and HIVE3 interventions will take place. Then, the team will conduct a joint workshop session because it is consistent with the concept that the intervention must retain relevance to MSM at all points along the HIV testing pathway, including in the HCF and among their peer-groups. The next step will be produce a revised combined version of the original intervention manuals before the workshop and conduct a series of facilitated simulation exercises with role-play over a 4-day period. Participants will work through each of the intervention levels, focusing on the intersectional stigma content and reviewing our approach to linking the different levels and creating opportunities for safe contact between HCF staff and MSM.
STEP 4: PRODUCE Based on the feedback from the simulation workshop participants and our observations of their engagement with the activities, the study team will determine what content and approaches to incorporate into the adapted intervention manual and which content and processes to edit or forego. In our decision-making process, the study team will give priority consideration to maintaining components that have the highest consistency with scientific literature on intersectional stigma, local cultural relevance, and likelihood to be fun/enjoyable-key requisites for successful intervention uptake.
STEP 5: TOPIC The study team will engage topic experts to review the adapted manual and provide feedback on its congruence with the original intervention and local sociocultural relevance. A copy of the adapted, combined multi-level intervention manual will be provided to the principal investigators of the original separate level interventions. Ghanaian MSM who lead PORSH and YAHR (our two civil-society organization partners that work with Ghanaian MSM) will give feedback that is key to the local cultural relevance and intervention implementation.
STEP 6: INTEGRATE In this step, feedback provided by the topic experts will be taken and summarized in a report that will be distributed to the entire investigative team, including our key local partners. The feedback will be discussed to develop follow-up clarifying questions to the topic experts, as necessary, before making final revisions to the multi-level intervention manual.
STEP 7: TRAIN The study team will also produce a training manual to standardize training and permit future replication of the intervention in other settings. This will provide comprehensive training to study staff whose roles are dedicated to delivering the intervention. In addition, the development of multi-faceted training will take place to facilitate comprehension and retention of training concepts, using strategies that Drs. Nyblade and Nelson has successfully deployed in other HIV prevention research projects. This will include conducting a joint (including teams from both cities) rehearsal of the protocol prior to implementation in the RCT with HCF staff and MSM who are not part of the trial.
RANDOMIZATION PROCEDURES Matched pairing of study facilities: the study will assign four HCFs in each study city to intervention and control groups by matching the size of HCF facility staff censure. In every city, the plan is to first stratify four clinics into a pair of two larger clinics and a pair of two smaller clinics, and then randomly assign one larger and one smaller clinic to either arm. HCFs will be assigned using a randomization sequence created in SAS 9.4 with a 1:1 allocation using random block sizes of four by an independent research assistant. A separate research assistant will open the sealed envelopes to identify group assignment immediately after completion of baseline data collection.
Random assignment of MSM participants. Consented/eligible MSM will be randomized in a 1:1 ratio to intervention versus control arm. A block-randomization approach using a random numbers generator to assign participants to the study arms will be employed, which ensures that the number of participants assigned to the intervention arm in each of the two study cities (or blocks) is approximately equal to the control arm.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Sequential
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Intervention | Experimental | Behavioral: Health Policy Plus (HP+), Behavioral: Many Men Many Voices (3MV), Behavioral: HIV Education, Empathy and Empowerment (HIVE3)This arm consists of 1) MSM who receive the intervention (not wait listed) and healthcare facility staff who work at health facilities that have been chosen for the intervention. |
| Wait listed | No intervention | –Participants in this arm (MSM and staff at health facilities that were wait listed) will complete assessments, but will receive the intervention after the experimental arm of the study. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (23 listed)
- Employed at one of the eight facilities identified for this study and identified with a potential to encounter MSM clients.
- Biologically male at birth
- Currently self-identify as cisgender man
- Report sexual activity with another man at least once within the previous six months and report that they are HIV-negative or status unknown.
- Employed at a study participating facility.
Key exclusion criteria (4 listed)
- HCF staff will be excluded if they anticipate leaving work at the HCF during the study period or have previously participated in HP.
- MSM will be excluded if they plan to move out of the area during the study period.
- Focus Group Discussions (FGDs)
- Those who do not meet the inclusion criteria listed above
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Health Policy Plus (HP+)HP+ is a stigma-reduction intervention that is designed to reduce stigmatizing attitudes and beliefs among all workers (clinical and non- clinical) in a healthcare facility. | Behavioural | Intervention |
| Many Men Many Voices (3MV)3MV is a group-level HIV prevention intervention designed specifically for use with Black men who have sex with men (MSM). It is a 7- session intervention that is facilitated by trained peers. The intervention has previously been adapted and used with MSM in Ghana. | Behavioural | Intervention |
| HIV Education, Empathy and Empowerment (HIVE3)The HIVE3 is a telephone-based peer support intervention. It utilizes trained peers, who are also MSM, to provide emotional, informational and affirming support via text message or phone. The intervention was developed specifically for use with MSM in Ghana and demonstrated acceptability and feasibility in a preliminary study in Ghana. | Behavioural | Intervention |
Primary outcome
HIV testing frequency (for MSM)
Time frame: Change from baseline at 3 months post- intervention
The intervention will be assessed in the number of completed HIV tests at 3 months compared to baseline. We will combine non-duplicative numbers of self-report and clinic-verified HIV tests (verification is only if an MSM had an HIV test performed at one of the healthcare facilities participating in the multi-level intervention) we are only measuring this outcome with MSM.
HIV testing frequency (for MSM)
Time frame: Change from baseline at 6 months post- intervention
The intervention will be assessed in the number of completed HIV tests at 6 months compared to baseline. We will combine non-duplicative numbers of self-report and clinic-verified HIV tests (verification is only if an MSM had an HIV test performed at one of the healthcare facilities participating in the multi-level intervention) we are only measuring this outcome with MSM.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Mar 2023.
- Derived from this study: PubMed 34843529Nelson LE, Nyblade L, Torpey K, Logie CH, Qian HZ, Manu A, Gyamerah E, Boakye F, Appiah P, Turner D, Stockton M, Abubakari GM, Vlahov D. Multi-level intersectional stigma reduction intervention to increase HIV testing among men who have sex with men in Ghana: Protocol for a cluster randomized controlled trial. PLoS One. 2021 Nov 29;16(11):e0259324. doi: 10.1371/journal.pone.0259324. eCollection 2021.
Related trials for HIV
RecruitingObservational study
Olfactory Function and Model-Based Behavior in People Living With HIV and SUD
HIV, Substance Use Disorder
Not yet recruiting
Adapting the ESTEEM Intervention to Improve Mental Health and PrEP Uptake Among Men at Risk of HIV
PrEP Use
RecruitingPhase 2
Evaluating the Safety and Immunogenicity of MTBVAC
HIV I Infection, Tuberculosis
Active, not recruiting
Evaluating the Effectiveness of a Mobile HIV Prevention App to Increase HIV and Sexually Transmitted Infections (STI) Testing and PrEP Initiation Among Rural Men Who Have Sex With Men
HIV Infections, STI
Not yet recruiting
PNF RCT to Decrease Alcohol Use and Increase HIV Prevention
HIV (Human Immunodeficiency Virus), Alcohol Misuse
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
LaRon E. Nelson, PhD principal investigator
Yale School of Nursing
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Health Policy Plus (HP+), Many Men Many Voices (3MV) and HIV Education, Empathy and Empowerment (HIVE3) in people with HIV and Stigma, run by Yale University at 1 site in Ghana.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 23 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 6 Mar 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Ghana. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
HIV testing frequency (for MSM) (time frame: Change from baseline at 3 months post- intervention). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04108078, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Mar 2023.